Application of artesunate as drug for treating systemic lupus erythematosus

Abstract

The invention relates to application of artesunate as a drug for treating systemic lupus erythematosus, adopting the artesunate with a molecular formula of C19H2808 for treating the systemic lupus erythematosus. The invention overcomes the defects that the prior common drug for treating SLE, such as cyclophosphamide, glucocorticoid, mycophenolate mofetil, hydroxychloroquine sulfate, leflunomide, azathioprine and the like has multiple side effects, is expensive, influences the life quality of a patient and even causes the patient to die because of some side effects, and the like. The invention has the advantages of cheap raw materials, easy availability, non or low toxicity, no pollution, mature production technology of a artesunate finished product, stable and reliable quality and little toxic side effects. Through comparison and study on a lupus mouse show that the efficacy of the artesunate is superior to a contrast group with little side effect. Therefore, the artesunate has a favorable prospect to treat the systemic lupus erythematosus.

Description

technical field [0001] The invention relates to a medicine for treating systemic lupus erythematosus, in particular to an application of artesunate as a medicine for treating systemic lupus erythematosus. Background technique [0002] Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by abnormal activation of T and B lymphocytes and the production of autoantibodies. One of the diseases of human health. The pathogenesis is still unclear. 80% of patients develop rashes (including discoid erythema and butterfly erythema) during the course of the disease. Almost all patients have pathological changes in kidney tissue. Clinically, 40%-80% of patients have obvious kidney disease. Involvement, lupus nephritis (LN) has become the most common secondary nephritis and one of the leading causes of death in SLE. [0003] Before the present invention, although cyclophosphamide (CTX), glucocorticoids, mycophenolate mofetil, hydroxychloroquine sulfate (HCQ), leflun...

AI Technical Summary

Problems solved by technology

[0003] Before the present invention, although cyclophosphamide (CTX), glucocorticoids, mycophenolate mofetil, hydroxychloroquine sulfate (HCQ), leflunomide, azathioprine, etc. are the commonly used drugs for the treatment of SLE at present, some biological agents are also Try to apply, but these drugs bring more side effects and are more expensive, which directly affects the quality of life of patients, and some side effects have even become one of the direct causes of death of patients

Images